Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.79
−$0.09 · -1.53%
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Previous close
$5.79
−$0.09 · -1.53%
After-hours
$5.79
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Day range
Current $5.79
52-week range
Current $5.79
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
60
Fair Value
Sentiment
49
Mixed
Risk
66
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Day range
Current $5.79
52-week range
Current $5.79
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 596.82K USD | 510.36K USD | 350.13K USD | — | — |
| Cost of goods sold | 638.97K USD | 355K USD | 196.69K USD | — | — |
| Gross profit | −42.15K USD | 155.36K USD | 153.45K USD | — | — |
| Research and development | 1.6M USD | 491.35K USD | — | — | — |
| Selling, general, and administrative | 3.63M USD | 1.13M USD | 160.56K USD | 2.32M USD | 1.72M USD |
| Operating expenses | 5.23M USD | 1.62M USD | 163.29K USD | 2.32M USD | 1.72M USD |
| Interest income | 80.16K USD | 11.81K USD | 290 USD | 813 USD | 764 USD |
| Interest expense | — | 772 USD | 2.14K USD | — | — |
| Depreciation and amortization | 209.56K USD | 104.74K USD | 2.45K USD | — | — |
| Operating income | −5.27M USD | −1.46M USD | −9.85K USD | −2.32M USD | −1.72M USD |
| Net income | −8.31M USD | −1.41M USD | 13.56K USD | 3.79M USD | 8.7M USD |
Company facts updated Oct 9, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
